Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026)
Zoetis' (ZTS) quarterly Total Non-Current Liabilities came in at $11.6 billion in Q2 2026, up 26.15% year-over-year from $9.2 billion in Q2 2025, and little changed quarter-over-quarter from $11.6 billion in Q1 2026.
Analysis
Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Total Non-Current Liabilities for 15 consecutive years, with $11.6 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 26.15% year-over-year to $11.6 billion in Q2 2026; TTM through Jun 2026 was $11.6 billion, a 26.15% increase from a year earlier, with the FY2025 full-year figure at $11.8 billion, up 28.32% from the prior year.
- Total Non-Current Liabilities was $11.6 billion for Q2 2026 at Zoetis, roughly flat from $11.6 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $11.8 billion in Q4 2025 and troughed at $8.8 billion in Q3 2023.
- A 5-year average of $9.5 billion and a median of $9.0 billion in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities dropped 12.08% in 2023 and rose 28.32% in 2025, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $10.3 billion in 2022, then decreased by 12.08% to $9.0 billion in 2023, then advanced by 1.89% to $9.2 billion in 2024, then rose by 28.32% to $11.8 billion in 2025, then retreated by 1.34% to $11.6 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $11.6 billion (Q2 2026), $11.6 billion (Q1 2026), and $11.8 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 542.10 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | 11.64 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 6.42 Bn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 1.02 Bn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | 10.82 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | 1.31 Mn |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.64 Bn |
| Mar 31, 2026 | 11.64 Bn |
| Dec 31, 2025 | 11.80 Bn |
| Sep 30, 2025 | 9.49 Bn |
| Jun 30, 2025 | 9.23 Bn |
| Mar 31, 2025 | 9.17 Bn |
| Dec 31, 2024 | 9.20 Bn |
| Sep 30, 2024 | 8.85 Bn |
| Jun 30, 2024 | 8.94 Bn |
| Mar 31, 2024 | 9.02 Bn |
| Dec 31, 2023 | 9.02 Bn |
| Sep 30, 2023 | 8.77 Bn |
| Jun 30, 2023 | 8.85 Bn |
| Mar 31, 2023 | 9.00 Bn |
| Dec 31, 2022 | 10.26 Bn |
| Sep 30, 2022 | 8.77 Bn |
| Jun 30, 2022 | 8.94 Bn |
| Mar 31, 2022 | 8.95 Bn |
| Dec 31, 2021 | 9.10 Bn |
| Sep 30, 2021 | 8.77 Bn |